Drug Firms Will Benefit From Cautious Estimates Of Part D Impact – Analyst
Drug manufacturers' conservative estimates about the impact of the Medicare prescription drug benefit will pay off in 2006, Alliance analyst Norm Fidel suggested at the JP Morgan Healthcare conference Jan. 12
You may also be interested in...
Below are excerpts from remarks on Medicare Part D made by executives at the Jan. 4-5 Morgan Stanley Pharmaceutical CEOs Unplugged conference in New York. Most CEOs are sticking with conservative forecasts for now that Medicare will have at most a modest impact on their business. While Merck and GlaxoSmithKline did not mention Medicare in their presentations, Pfizer devoted most of its talk to Part D, reporting that it is "retooling" to take advantage of Medicare opportunities.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials